These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34532977)

  • 1. The rise of deep learning and transformations in bioactivity prediction power of molecular modeling tools.
    Bule M; Jalalimanesh N; Bayrami Z; Baeeri M; Abdollahi M
    Chem Biol Drug Des; 2021 Nov; 98(5):954-967. PubMed ID: 34532977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial intelligence to deep learning: machine intelligence approach for drug discovery.
    Gupta R; Srivastava D; Sahu M; Tiwari S; Ambasta RK; Kumar P
    Mol Divers; 2021 Aug; 25(3):1315-1360. PubMed ID: 33844136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial Intelligence, Machine Learning, and Deep Learning in Real-Life Drug Design Cases.
    Muller C; Rabal O; Diaz Gonzalez C
    Methods Mol Biol; 2022; 2390():383-407. PubMed ID: 34731478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intelligently Applying Artificial Intelligence in Chemoinformatics.
    Sharma S; Sharma D
    Curr Top Med Chem; 2018; 18(20):1804-1826. PubMed ID: 30465503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR.
    Tropsha A; Isayev O; Varnek A; Schneider G; Cherkasov A
    Nat Rev Drug Discov; 2024 Feb; 23(2):141-155. PubMed ID: 38066301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery.
    Nayarisseri A; Khandelwal R; Tanwar P; Madhavi M; Sharma D; Thakur G; Speck-Planche A; Singh SK
    Curr Drug Targets; 2021; 22(6):631-655. PubMed ID: 33397265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel artificial intelligence protocol to investigate potential leads for diabetes mellitus.
    Gong JN; Zhao L; Chen G; Chen X; Chen ZD; Chen CY
    Mol Divers; 2021 Aug; 25(3):1375-1393. PubMed ID: 33687591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The power of deep learning to ligand-based novel drug discovery.
    Baskin II
    Expert Opin Drug Discov; 2020 Jul; 15(7):755-764. PubMed ID: 32228116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine learning approaches and their applications in drug discovery and design.
    Priya S; Tripathi G; Singh DB; Jain P; Kumar A
    Chem Biol Drug Des; 2022 Jul; 100(1):136-153. PubMed ID: 35426249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial intelligence: Machine learning approach for screening large database and drug discovery.
    Parvatikar PP; Patil S; Khaparkhuntikar K; Patil S; Singh PK; Sahana R; Kulkarni RV; Raghu AV
    Antiviral Res; 2023 Dec; 220():105740. PubMed ID: 37935248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Deep Learning-Based Quantitative Structure-Activity Relationship System Construct Prediction Model of Agonist and Antagonist with High Performance.
    Matsuzaka Y; Uesawa Y
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Neural Networks for QSAR.
    Xu Y
    Methods Mol Biol; 2022; 2390():233-260. PubMed ID: 34731472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Structure-Based Drug Discovery Paradigm.
    Batool M; Ahmad B; Choi S
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial intelligence in drug discovery: recent advances and future perspectives.
    Jiménez-Luna J; Grisoni F; Weskamp N; Schneider G
    Expert Opin Drug Discov; 2021 Sep; 16(9):949-959. PubMed ID: 33779453
    [No Abstract]   [Full Text] [Related]  

  • 15. Demystifying Multitask Deep Neural Networks for Quantitative Structure-Activity Relationships.
    Xu Y; Ma J; Liaw A; Sheridan RP; Svetnik V
    J Chem Inf Model; 2017 Oct; 57(10):2490-2504. PubMed ID: 28872869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep Learning in Virtual Screening: Recent Applications and Developments.
    Kimber TB; Chen Y; Volkamer A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of artificial intelligence to drug design and discovery in the big data era: a comprehensive review.
    Tripathi N; Goshisht MK; Sahu SK; Arora C
    Mol Divers; 2021 Aug; 25(3):1643-1664. PubMed ID: 34110579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery.
    Tsou LK; Yeh SH; Ueng SH; Chang CP; Song JS; Wu MH; Chang HF; Chen SR; Shih C; Chen CT; Ke YY
    Sci Rep; 2020 Oct; 10(1):16771. PubMed ID: 33033310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep Learning Applied to Ligand-Based De Novo Drug Design.
    Palazzesi F; Pozzan A
    Methods Mol Biol; 2022; 2390():273-299. PubMed ID: 34731474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.